MedTrace Logo

Metabolic Effects of Treatment in Intermediate and High-Risk Prostate Cancer

NCT01599182 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2015-06-23

No results posted yet for this study

Summary

This study will work towards understanding the changes in your body (metabolism) that develop with treatment in prostate cancer. Hormonal therapies such as ADT often result in detrimental changes in body composition, including lean tissue loss and fat gains, compared to those patients receiving radiation therapy. These changes in body composition are linked to risk of diabetes and cardiovascular disease in survivorship. The investigators will be evaluating 50 patients to primarily examine the changes in metabolism, nutrition, physical function and body composition at the end of treatment, 6 weeks and 6 months following the end of treatment. Patients will continue to be followed every 6 months for up to 5 years following the end of treatment. The investigators findings will provide a new perspective for future work and novel approaches in the treatment of prostate cancer.

Conditions

Sponsors & Collaborators

  • Grand River Regional Cancer Centre

    collaborator OTHER

  • University of Waterloo

    lead OTHER

Principal Investigators

  • Marina Mourtzakis, PhD · University of Waterloo

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01599182 on ClinicalTrials.gov